I

Innocrin Pharmaceuticals, Inc.

3 employees

Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer.

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Health Care
Medical
Pharmaceutical

Date founded

2014

Funding rounds raised

Total raised

$28M

from 1 investors over 1 rounds

I

Innocrin Pharmaceuticals, Inc. raised $28M on April 14, 2015

Investors: Eshelman Ventures, LLC

FAQ